You are here

RNAi

Bayer helps Harvard spinout Vesigen to $28.5M series A

Fierce Biotech

Wed, 07/22/20 - 10:39 am

Vesigen Therapeutics

Alnylam's RNAi therapy Givlaari shows lasting effect one year into treatment, new data show

Fierce Pharma

Tue, 06/30/20 - 10:51 am

acute hepatic porphyria

Dicerna nabs speedy review voucher for leading RNAi drug

Fierce Biotech

Thu, 06/18/20 - 10:36 am

priority review

Alnylam sets up 3rd potential RNAi approval with a showcase of positive lumasiran data

Endpoints

Sun, 06/7/20 - 10:32 pm

clinical trials

Alnylam nabs speedy review, setting up 3rd possible approval in 3 years

Endpoints

Tue, 05/26/20 - 11:12 am

Alnylam, Vir plan year-end trial of new RNAi COVID-19 antiviral

Fierce Biotech

Mon, 05/4/20 - 10:37 am

Vir Biotechnology

clinical trials

Alnylam's vutrisiran gets fast-track treatment at the FDA

Fierce Biotech

Tue, 04/14/20 - 09:44 am

Blackstone backs Alnylam with up to $2B investment

BioPharma Dive

Mon, 04/13/20 - 09:50 pm

Arrowhead Pharmaceuticals files for regulatory clearance to begin phase 1/2a study of ARO-ENaC for treatment of cystic fibrosis

Pharmaceutical Business Review

Mon, 04/13/20 - 10:50 am

Arrowhead Pharmaceuticals

clinical trials

cystic fibrosis

After putting aside a bitter legal feud, Alnylam and Dicerna chiefs make nice with an RNAi collaboration

Endpoints

Mon, 04/6/20 - 10:29 am

John Maraganore

Douglas Fambrough

Vir and Alnylam expand collaboration to advance investigational RNAi therapeutics targeting host factors for treatment of COVID-19

Pharmaceutical Business Review

Fri, 04/3/20 - 11:15 am

Vir Biotechnology

drug development

Alnylam Pharmaceuticals and Gen sign distribution agreement in Turkey for ONPATTRO (patisiran)

Pharmaceutical Business Review

Thu, 03/26/20 - 10:22 am

hATTR amyloidosis

Alnylam, Vir team up to develop siRNAs to tackle COVID-19

Fierce Biotech

Wed, 03/4/20 - 10:52 am

Vir Biotechnology

After big year, RNAi drugmakers compete to prove what comes next

BioPharma Dive

Sat, 01/18/20 - 07:37 pm

Arrowhead Pharmaceuticals

Dicerna Pharmaceuticals

JPM: Alnylam CEO looks to action-packed 2020 on the heels of Givlaari approval

Fierce Pharma

Tue, 01/14/20 - 10:44 am

John Maraganore

With trial win, Alnylam to seek approval for first treatment of rare kidney disease

Biopharma Dive

Tue, 12/17/19 - 10:29 am

clincial trials

Primary Hyperoxaluria

3 Soaring Biotech Stocks to Watch in December

Motley Fool

Mon, 12/2/19 - 10:40 am

Arrowhead Pharmaceuticals

Adverum Biotechnologies

Second RNAi Drug Approved: Biotech Investors Should Pay Attention to This New Drug Class

Motley Fool

Sat, 11/23/19 - 04:05 pm

FDA's rapid review pace nets an early approval for Alnylam's second drug

Biopharma Dive

Wed, 11/20/19 - 10:51 pm

Dicerna scores broad, 'rest of liver' deal with Novo Nordisk, bagging $225M in cash to hit some 30 targets with RNAi platform

Endpoints

Mon, 11/18/19 - 11:33 pm

Pages